- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04891198
ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors
An Open, Single-arm, Multi-center Phase II Clinical Study of ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors
Study Overview
Detailed Description
The enrolled subjects will receive envafolimab treatment during the treatment phase, and the dosage and usage is 400 mg envafolimab subcutaneously injected every four weeks, 28 days as a treatment cycle.
The study treatment continued to reach the standard of stopping treatment. During this period, the efficacy, safety and PK will be evaluated according to the visit process.In this study, imaging examinations (CT or MRI) were used to evaluate the efficacy at baseline and during the study period. The results of the examination were evaluated based on the efficacy evaluation criteria for solid tumors (RECIST1.1) and irRECIST criteria.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Lin Shen, MD
- Phone Number: 86-10-88196340
- Email: doctorshenlin@sina.cn
Study Locations
-
-
-
Beijing, China
- Recruiting
- Beijing Cancer Hospital
-
Contact:
- Lin Shen, MD
- Phone Number: 86-010-88196340
- Email: doctorshenlin@sina.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Volunteer to participate and sign the informed consent form.
- Age ≥ 18 years old, regardless of gender.
- Patients with unresectable or metastatic advanced solid tumors confirmed by histology or cytology.
Subjects with advanced malignant solid tumors who had disease progression or intolerance and no satisfactory alternative treatment with at least first-line standard treatment.
Note: If recurrence occurs during adjuvant/neoadjuvant therapy or within 6 months after completion, adjuvant/neoadjuvant therapy is considered to be the first-line treatment for advanced disease.
- Have not received immune checkpoint inhibitor treatment.
- Patients with the following tumor types: small cell lung cancer, cervical cancer, endometrial cancer, ovarian cancer, vulvar cancer, neuroendocrine tumors, salivary gland cancer, thyroid papillary or follicular cancer, skin squamous cell carcinoma, skin malignant melanoma , Merkel cell tumor, head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, bladder cancer, cholangiocarcinoma, etc.
- Have tissue and blood samples that can detect TMB specimen.
- There is at least one measurable lesion (RECIST 1.1 standard).
- ECOG score of 0 or 1.
- The expected survival period is ≥ 12 weeks.
Sufficient organ and bone marrow function (no hematopoietic growth factor, blood transfusion or platelet therapy was given within 7 days before the first study drug treatment):
- Blood routine: absolute neutrophil count (ANC) ≥1.5×109/L, platelet ≥100×109/L and hemoglobin ≥90 g/L;
- Liver function: serum total bilirubin ≤ 1.5 times the upper limit of the normal reference range (×ULN); when there is no liver metastasis, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; ALT and AST ≤5 × ULN in liver metastasis;
- Renal function: subjects with serum creatinine ≤ 1.5 × ULN or creatinine level> 1.5 times ULN, measured or calculated according to Cockcroft-Gault formula creatinine clearance rate ≥ 60.0 mL / min;
- Coagulation function: International normalized ratio (INR) ≤ 1.5 and partially activated prothrombin time (aPTT) ≤ 1.5 × ULN; (For patients undergoing anticoagulation therapy, the investigator judges that both INR and aPTT are safe and effective treatments Within);
- Heart function: left ventricular ejection fraction (LVEF) detected by echocardiography>50%
- Women with fertility must have a negative serum pregnancy test within 7 days before the first medication. Reproductive male or female patients voluntarily use effective contraceptive methods, such as double-barrier contraceptive methods, condoms, oral or injectable contraceptives, intrauterine devices, etc., from signing the informed consent until 90 days after the last study medication. All female patients will be considered fertile unless the female patient has been naturally menopausal, has undergone artificial menopause, or has been sterilized (such as hysterectomy, bilateral adnexectomy).
Exclusion Criteria:
- Participate in the clinical trials of other investigational drugs or investigational devices within 28 days before the first medication; or have received anti-tumor treatment within 2 weeks, including but not limited to chemotherapy and radiotherapy (allowed to complete the palliative at least 1 week before the study drug treatment Radiotherapy) or targeted therapy.
The toxicity of previous anti-tumor treatments has not recovered to 0 or 1 level (hair loss, peripheral neurotoxicity caused by chemotherapy ≤ 2 can be selected). Subjects who need to use corticosteroids (> 10 mg/day prednisone equivalent dose) or other immunosuppressive drugs for systemic therapy within 14 days before the study drug is administered.
Note: If there is no active autoimmune disease, inhaled or topical steroid hormones, or adrenal hormone replacement therapy with a prednisone equivalent dose of ≤ 10 mg per day is allowed. Allow short-term (≤ 7 days) use of glucocorticoids for preventive treatment (for example, for subjects with a history of severe allergies, when other anti-allergic drugs cannot be used instead to prevent allergy to contrast agents, researchers can use glucocorticoids according to local diagnosis and treatment routines Prevention) or for the treatment of non-autoimmune diseases (for example, delayed type hypersensitivity caused by contact allergens).
- Subjects who have active, or have had autoimmune diseases or risks that may recur (for example, an organ transplant that requires immunosuppressive therapy). However, subjects with type I diabetes, hypothyroidism requiring only hormone replacement therapy, or skin diseases that do not require systemic treatment (for example, vitiligo, psoriasis, or hair loss) are allowed to be included in the group. For any uncertain situation, it is recommended to consult the sponsor's medical monitor before signing the informed consent.
- Major surgery (except for biopsy) or the surgical incision did not heal completely within 4 weeks before the first study drug treatment.
- Suffered from other known malignant tumors within 2 years before enrollment (except for treated skin basal cell carcinoma, skin squamous cell carcinoma and/or carcinoma in situ after radical resection).
- Untreated brain metastases and Symptomatic brain metastasis or spinal cord compression after treatment ; for patients with brain metastases who have previously received treatment, if the clinical and imaging evidence does not indicate disease progression within 4 weeks before the first study drug treatment, and 2 weeks before the first administration There is no need to receive corticosteroid treatment and can be considered for inclusion.
- Previous history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia, symptomatic interstitial lung disease or any evidence of active pneumonia detected by chest CT scan within 4 weeks prior to first study drug therapy.
- Subjects with a history of active tuberculosis infection within 1 year before the first study administration and a history of active tuberculosis infection more than 1 year ago were considered suitable for inclusion if the investigator determined that there was no evidence of active tuberculosis at present.
- Mental or substance abuse disorders that are known to interfere with test compliance.
- A history of human immunodeficiency virus (HIV) infection or an active bacterial or fungal infection requiring systematic treatment in the 14 days prior to initial study drug therapy.
- Uncontrolled hepatitis virus infection (positive for HBV DNA or HCV RNA) .
- Within 4 weeks of initial administration, there is ascites requiring drainage or diuretic treatment, or pleural or pericardial effusion requiring drainage and/or symptoms of tachypnea.
- Cardiovascular disease with significant clinical significance.
- Receive live or attenuated live vaccine within 4 weeks prior to the first study drug treatment.
- History of severe allergic reaction to humanized antibodies or fusion proteins.
- Any other disease , and the investigator had reason to suspect that the patient was not eligible for study drug therapy.
- Part II: The results of tumor tissue samples were MSI-H
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Subjects with TMB-H/TMB-L
Subjects receive KN035 400 mg Subcutaneously on Day 1 and day 15 of cycle 1 and on day 1 of every subsequent 4-week cycle (Q4W)
|
Subcutaneous injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: up to approximately half past one year
|
To evaluate the objective response rate of Envafolimab in patients with advanced solid tumors with high tumor mutation burden (TMB-H) [Blind Independent Imaging Review Committee (BIRC) evaluation]
|
up to approximately half past one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: Up to approximately half past one year
|
To evaluate the objective response rate of Envafolimab in patients with TMB-H and TMB-L advanced solid tumors (investigator assessment)
|
Up to approximately half past one year
|
DCR
Time Frame: Up to approximately half past one year
|
To evaluate the disease control rateof Envafolimab in patients with TMB-H and TMB-L advanced solid tumors
|
Up to approximately half past one year
|
DoR
Time Frame: Up to approximately half past one year
|
To evaluate the duration of remission of Envafolimab in patients with TMB-H and TMB-L advanced solid tumors
|
Up to approximately half past one year
|
PFS
Time Frame: Up to approximately half past one year
|
To evaluate the progression-free survival of Envafolimab in patients with TMB-H and TMB-L advanced solid tumors
|
Up to approximately half past one year
|
OS
Time Frame: Up to approximately half past one year
|
To evaluate the overall survival of Envafolimab in patients with TMB-H and TMB-L advanced solid tumors
|
Up to approximately half past one year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lin Shen, MD, Peking University Cancer Hospital & Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KN035-CN-012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
Pyxis Oncology, IncRecruiting
Clinical Trials on Envafolimab
-
Anhui Provincial Cancer HospitalNot yet recruitingNon-small Cell Lung Cancer Stage IIIChina
-
Fudan UniversityNot yet recruitingLocally Advanced Rectal Carcinoma | MSI-High
-
The First Affiliated Hospital of Xiamen UniversityActive, not recruitingNon-small Cell Lung Cancer Stage IVChina
-
Northern Jiangsu Province People's HospitalRecruiting
-
Peking Union Medical College HospitalNot yet recruitingEfficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruiting
-
Hairong LiuNot yet recruiting
-
Jiangsu Cancer Institute & HospitalNot yet recruiting
-
Chipscreen Biosciences, Ltd.Active, not recruitingNon Small Cell Lung CancerChina
-
Anhui Chest HospitalNot yet recruitingCarcinoma, Non-Small-Cell Lung